Results 31 to 40 of about 6,092,576 (159)

Is the Safety of Finasteride Correlated With Its Route of Administration: Topical Versus Oral? A Pharmacovigilance Study With Data From the United States Food and Drug Administration Adverse Event Reporting System. [PDF]

Int J Dermatol
ABSTRACT Background The United States Food and Drug Administration (FDA) approved oral finasteride for androgenetic alopecia. In 2022, approximately 2.6 million U.S. men used it for hair loss and prostate conditions. Post‐finasteride syndrome (PFS), proposed in 2012, involves persistent sexual and neuropsychiatric adverse events (AEs) after cessation ...
Gupta AK, Talukder M, Keene SA, Bamimore MA.   +3 more
europepmc   +2 more sources

A Pharmacogenetic Survey of Androgen Receptor (CAG)N and (GGN)N Polymorphisms in Patients Experiencing Long Term Side Effects after Finasteride Discontinuation

The International Journal of Biological Markers, 2014
Finasteride is a steroid 5-alpha-reductase inhibitor, approved for the treatment of androgenetic alopecia (AGA) and benign prostate hyperplasia. In some patients the treatment is associated with adverse side effects that could become persistent after ...
Erika Cecchin PhD, Elena De Mattia, Giorgio Mazzon, Sabina Cauci, Carlo Trombetta, Giuseppe Toffoli   +5 more
doaj   +2 more sources

5α-Reductase Isoenzymes: From Neurosteroid Biosynthesis to Neuropsychiatric Outcomes [PDF]

NeuroSci
5a-reductase (5a-R) isozymes are essential for androgen metabolism and neurosteroid biosynthesis, linking endocrinology and neuropsychiatry. This systematic review, conducted in accordance with PRISMA 2020 guidelines, aimed to synthesize current evidence
Carmen Rodriguez-Cerdeira
doaj   +2 more sources

8679 Case: The Sexual, Physical and Psychological Effects of Post-Finasteride Syndrome [PDF]

Journal of the Endocrine Society
Abstract Disclosure: E.M. Lonergan: None. S.M. Maher: None. I. Yaseen: None. D.B. O'Shea: None. Post-finasteride syndrome (PFS) is an increasingly recognised disorder with a myriad of physical and neuropsychiatric symptoms persisting for greater than three months in a small proportion of patients treated with Finasteride ...
Lonergan, Eibhlin Marie, Maher, Sean Martin, Yaseen, Ibrahim, O'Shea, Donal Brendan   +3 more
openaire   +2 more sources

Post-Finasteride Syndrome: Survey of Dermatologists From the Spanish Hair and Nail Disorders Group

Actas Dermo-Sifiliográficas
Background and objective: Post-finasteride syndrome (PFS) refers to a set of persistent symptoms reported by patients after discontinuation of 5-alpha-reductase inhibitors (5-ARIs).
O.M. Moreno-Arrones, D. Saceda-Corralo, J.L. Gómez-Cano, A. Gómez-Zubiaur, J.M. Mir-Bonafé, C. Serrano-Falcón, G. Garnacho-Saucedo, R. Grimalt, A. Combalia, E. Fernández, S. Vañó-Galván   +10 more
doaj   +2 more sources

Altered methylation pattern of the SRD5A2 gene in the cerebrospinal fluid of post-finasteride patients: a pilot study [PDF]

Endocrine Connections, 2019
Context: Post-finasteride syndrome (PFS) occurs in patients with androgenic alopecia after suspension of the finasteride treatment, leading to a large variety of persistent side effects.
Roberto Cosimo Melcangi, Livio Casarini, Marco Marino, Daniele Santi, Samantha Sperduti, Silvia Giatti, Silvia Diviccaro, Maria Grimoldi, Donatella Caruso, Guido Cavaletti, Manuela Simoni   +10 more
doaj   +2 more sources

Efficacy of Hair Mesotherapy With Biomimetic Peptides and Micronutrients in Patients With Androgenetic Alopecia: A Retrospective Observational Study [PDF]

J Cosmet Dermatol
ABSTRACT Background Hair mesotherapy is increasingly used in the management of androgenetic alopecia (AGA), yet standardized treatment protocols and controlled clinical data are limited. Aims This study aimed to evaluate the efficacy and safety of a mesotherapy formulation containing biomimetic peptides, vitamins, and micronutrients in patients with ...
Köse Ö, Borlu M.
europepmc   +2 more sources

Post-finasteride syndrome and post-SSRI sexual dysfunction: two sides of the same coin?

, 2018
Sexual dysfunction is a clinical condition due to different causes including the iatrogenic origin. For instance, it is well known that sexual dysfunction may occur in patients treated with antidepressants like selective serotonin reuptake inhibitors (SSRI). A similar side effect has been also reported during treatment with finasteride, an inhibitor of
Giatti, Silvia, Diviccaro, Silvia, Panzica, Giancarlo, Melcangi, Roberto Cosimo   +3 more
openaire   +3 more sources

Pharmacological Management of Pattern Hair Loss

Indian Journal of Plastic Surgery, 2021
Pattern hair loss (PHL) is a condition that worsens with time and the only way it can be slowed down is with pharmacological intervention. Pharmacological treatments for PHL, from an evidenced-based perspective with respect to safety and efficacy, are ...
Sandeep Suresh Sattur, Indu Sandeep Sattur   +1 more
doaj   +1 more source

Post‐Finasteride Syndrome or Pre‐Existing Vulnerability? Rethinking Patient Selection [PDF]

Journal of Cosmetic Dermatology
Rivetti N.
openaire   +3 more sources